Beperminogene perplasmid for the treatment of critical limb ischemia

References

• Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg 2007;33:S1-70
   PubMed Web of Science ®Google Scholar
• Małecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the 21st century--a new face of disease. Atherosclerosis 2009;206:328-34
   PubMed Web of Science ®Google Scholar
• Sasaki S, Sakuma M, Yasuda K. Current status of Thromboangiitis obliterans (Buerger’s disease) in Japan. Int J Cardiol 2000;75:S175-81
   Google Scholar
• Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc 2014;3(2):e000697
   PubMed Web of Science ®Google Scholar
• Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-23
   PubMed Web of Science ®Google Scholar
• Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis Obliterans (Buerger’s disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998;28:964-5
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Shah M, Luciano A, et al. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 2001;104:753-5
   PubMed Web of Science ®Google Scholar
• Mäkinen K, Manninen H, Hedman M, et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebocontrolled, double-blinded phase II study. Mol Ther 2002;6:127-33
   PubMed Web of Science ®Google Scholar
• Comerota AJ, Throm RC, Miller KA, et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 2002;35:930-6
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Mohler ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, doubleblind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108:1933-8
   PubMed Web of Science ®Google Scholar
• Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 2006;17:683-91
   PubMed Web of Science ®Google Scholar
• Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008;16:972-8
   PubMed Web of Science ®Google Scholar
• Belch J, Hiatt WR, Baumgartner I, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011;377:1929-37
   PubMed Web of Science ®Google Scholar
• Henry TD, Hirsch AT, Goldman J, et al. Safety of a non-viral plasmid encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study. Gene Ther 2011;18:788-94
   PubMed Web of Science ®Google Scholar
• Points to Consider on Plasmid DNA Vaccines for Preventative Infectious Disease Indications; Availability. FDA, HHS, 1996. Available from: www.gpo.gov/fdsys/granule/FR-1996-12-27/96-32930/content-detail.html
   Google Scholar
• Miyazawa K, Shimomura T, Kitamura A, et al. Molecular cloning and sequence analysis of the cDNA for a human serine protease responsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem 1993;268:10024-8
   PubMed Web of Science ®Google Scholar
• Morishita R, Nakamura S, Hayashi S, et al. Contribution of a vascular modulator, hepatocyte growth factor (HGF), to the pathogenesis of cardiovascular disease. J AtherosclerThromb 1998;4:128-34
   Google Scholar
• Hayashi S, Morishita R, Nakamura S, et al. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation 1999;100:II301-8
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Morishita R, Higaki J, et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens 1996;14:1067-72
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Morishita R, Higaki J, et al. Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun 1995;215:483-8
   PubMed Web of Science ®Google Scholar
• Kaga T, Kawano H, Sakaguchi M, et al. Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor. Vascul Pharmacol 2012;57:3-9
   PubMed Web of Science ®Google Scholar
• Taniyama Y, Morishita R, Aoki M, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2001;8:181-9
   PubMed Web of Science ®Google Scholar
• Taniyama Y, Morishita R, Hiraoka K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001;104:2344-50
   PubMed Web of Science ®Google Scholar
• Morishita R, Makino H, Aoki M, et al. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol 2011;31:713-20
   PubMed Web of Science ®Google Scholar
• Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebo controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008;118:58-65
   PubMed Web of Science ®Google Scholar
• Powell RJ, Goodney P, Mendelsohn FO, et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg 2010;52:1525-30
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Yasuda K, Iwai T, et al. Randomized, double-blind, placebo controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010;17:1152-61
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Yasuda K, Iwai T, et al. Transfection of human HGF plasmid DNA improves limb salvage in Buerger’s disease patient with critical limb ischemia. Int Angiol 2011;30(2):140-9
   PubMed Web of Science ®Google Scholar